Stockscreener 앱 받기
150.97
0.81%
-1.24
시간 외 거래:
152.00
1.03
+0.68%
전일 마감가:
$152.21
열려 있는:
$152.36
하루 거래량:
1.33M
Relative Volume:
0.85
시가총액:
$22.13B
수익:
$9.61B
순이익/손실:
$1.53B
주가수익비율:
14.44
EPS:
10.453
순현금흐름:
$1.85B
1주 성능:
-2.11%
1개월 성능:
+6.81%
6개월 성능:
+32.37%
1년 성능:
-17.19%
1일 변동 폭
$149.64
$152.36
1주일 범위
$149.64
$160.20
52주 변동 폭
$110.03
$194.13
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
150.97 | 22.32B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
845.72 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.69 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.24 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.31 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.40 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Can BMYs Neuroscience Portfolio Help to Diversify Its Business? - The Globe and Mail
Biogen stock price target lowered to $217 from $219 at RBC Capital - Investing.com UK
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $217.00 - MarketBeat
Central Nervous System Biomarkers Market Growth & Industry - openPR.com
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Biogen Inc. $BIIB Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Ascent Group LLC Takes $341,000 Position in Biogen Inc. $BIIB - MarketBeat
Biogen Says Investors Can't Expand Alzheimer's Drug Suit - Law360
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syn - PharmiWeb.com
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - Yahoo Finance
Bioarctic's Leqembi Maintenance Therapy Launched in the United States - MarketScreener
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US By Investing.com - Investing.com Australia
Biogen Inc. stock underperforms Monday when compared to competitors - MSN
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US - Investing.com
Eisai and Biogen Launch LEQEMBI Companion™ Program to Enhance Resources for Alzheimer's Disease Treatment - Quiver Quantitative
Biogen told to pay $124M in patent dispute with Genentech - Fierce Pharma
Rothschild & Co Redburn Increases Biogen (NASDAQ:BIIB) Price Target to $150.00 - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Biogen to $150 From $149, Maintains Neutral Rating - MarketScreener
In Vitro Monoclonal Antibodies Market to hit US$ 8.4 Billion - openPR.com
Acetylcholinesterase Inhibitors Market to hit US$ 9.03 Billion - openPR.com
Can Biogen Inc. stock double in next 5 yearsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Grimes & Company Inc. Sells 18,310 Shares of Biogen Inc. $BIIB - MarketBeat
J. Safra Sarasin Holding AG Sells 7,635 Shares of Biogen Inc. $BIIB - MarketBeat
Mirae Asset Global Investments Co. Ltd. Raises Holdings in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a defensive play in 2025Oil Prices & Verified Swing Trading Watchlist - newser.com
A Look at Biogen (BIIB) Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism - simplywall.st
Biogen Idec : Biogen Idec Named Top Employer by Science Magazine - MarketScreener
Day 6 of Gains Streak for Biogen Stock with 18% Return (vs. 4.6% YTD) [10/3/2025] - Trefis
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biogen (BIIB) Gains as LEQEMBI Wins Australian Approval for Early Alzheimer’s Treatment - simplywall.st
[Updated 2026] Biotechnology Market Size & Sector Scope 2032 - openPR.com
Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - MSN
Biogen must pay $88 million more for use of infamous Cabilly patent - IAM Patent
Could Eisai Partnership and New LEQEMBI Approval Reshape Biogen's (BIIB) Alzheimer's Strategy? - simplywall.st
United States SMN1 Gene Replacement Market is expected to reach - openPR.com
Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength? - Yahoo Finance
Biogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Greenleaf Trust Raises Holdings in Biogen Inc. $BIIB - MarketBeat
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism - AD HOC NEWS
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns - FinancialContent
Biogen owes Genentech $88 million in MS drug dispute, US judge says - Reuters
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years - Benzinga
Biogen’s Bold Moves: Navigating the Market Waves - StocksToTrade
Biogen (NASDAQ:BIIB) Trading 8.1% HigherStill a Buy? - MarketBeat
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
1.26%
자본화:
|
볼륨(24시간):